THE ROYAL MARSDEN NATIONAL HEALTH SERVICE TRUST

Their core work

The Royal Marsden is one of the world's leading specialist cancer hospitals, based in London. Within EU research, they contribute clinical oncology expertise — from studying low-dose radiation effects on patients (MEDIRAD) to running clinical trials for brain cancer treatments (CLINGLIO) and providing real-world clinical imaging data for AI-driven prostate cancer diagnostics (ProCAncer-I). Their value lies in being a high-volume cancer treatment centre that can supply clinical data, patient cohorts, and frontline medical insight that laboratory-only institutions cannot.

What they specialise in

How they've shifted over time

RMH's early H2020 involvement (2017) centred on traditional clinical concerns — radiation safety (MEDIRAD) and drug-based cancer treatment trials (CLINGLIO). By 2020, their focus shifted decisively toward digital health, joining ProCAncer-I to contribute clinical imaging data for AI-driven cancer diagnostics. This mirrors the broader oncology sector's pivot from purely clinical research toward data-intensive, AI-assisted precision medicine.

RMH is moving toward AI and data-driven oncology, making them a strong clinical partner for digital health consortia that need real hospital imaging data and cancer patient cohorts.

How they like to work

RMH participates exclusively as a consortium partner, never as coordinator — consistent with their role as a clinical data and expertise provider rather than a research management organisation. With 66 unique partners across 19 countries from just 3 projects, they join large, multi-national consortia where their contribution is specialised clinical input. Working with them means gaining access to one of Europe's premier cancer hospitals, but project leadership and technical development will come from other partners.

Despite only three projects, RMH has connected with 66 distinct partners across 19 countries, reflecting their participation in large pan-European health consortia. Their network spans major European research hospitals, universities, and medical technology developers.

What sets them apart

As a world-renowned specialist cancer hospital operating within the UK's NHS, RMH offers something most research partners cannot: direct access to large-scale, real-world oncology clinical data and patient populations under a unified healthcare system. For consortium builders, this means a partner who can validate research outputs in an actual clinical setting, bridging the gap between laboratory findings and bedside application. Their NHS status also adds credibility and regulatory familiarity that academic-only partners lack.

Highlights from their portfolio

• MEDIRAD
  Largest funded project (EUR 678K) — studied real-world implications of medical radiation exposure, a topic with direct impact on millions of patients undergoing diagnostic imaging and radiotherapy.
• ProCAncer-I
  Most recent and forward-looking project — building an AI platform for prostate cancer precision care using annotated clinical imaging, representing RMH's pivot into digital health.
• CLINGLIO
  A Phase IIB clinical trial for malignant glioma treatment, demonstrating RMH's capacity to contribute to advanced-stage drug development trials.